Vadadustat

Overview

Vadadustat (PG-1016548) is a titratable, oral hypoxia-inducible factor prolyl hydroxylase ( HIF-PH ) inhibitor. Vadadustat is an erythropoiesis-stimulating agent and has the potential for anemia treatment in chronic kidney disease in vivo.

Application

Products | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Viral Infection | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Blood Disease | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Coronavirus Infection | Products > Disease Areas > Breast Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > HIF/HIF Prolyl-Hydroxylase

Product Information

• Catalog No.: HY-101277
• CAS No.: 1000025-07-9
• Molecular Formula: C14H11ClN2O4
• Molecular Weight: 306.70
• Purity: 99.70%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (8.15 mM); Clear solution
• Availability: In-stock

Source

Original product source